

05-08-06

1fw

Express Mail: EV 630723220 US



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RE Application of:

Confirmation No.: 1322  
Serial No.: 10/723,123  
Applicant: SCHAAP ET AL  
Filed: November 26, 2003  
Group Art Unit: 1645  
Examiner: BASKAR, P.  
For: COCCIDIOSIS VACCINES  
Attorney Docket: I-1998.407 US D2

May 4, 2006

**INFORMATION DISCLOSURE STATEMENT AND TRANSMITTAL**  
**OF FEE PURSUANT TO 37 CFR 1.97(c)**

**Mail Stop: Amendment**  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir/Madam:

To comply with 37 CFR §§1.97 and 1.98, Applicants submit the enclosed combined Form PTO/SB/08A and PTO/SB/08B, and copies of the cited information (to the extent required by the Patent Office).

In accordance with MPEP §§609 and 707.05(b), Applicants request that the enclosed statement be given thorough consideration, and that the Examiner make the cited information of record by initialing the statement next to each citation. Applicants request such initialing even if the Examiner does not consider: (1) the cited information to be sufficiently pertinent to use in a

rejection, or (2) the guidelines for a citation to have been fully satisfied. Applicants make this request so that the information will be cited on the face of a patent issuing from this patent application.

Applicants submit this statement in accordance with the duty to disclose information material to patentability under 37 CFR §1.56. Applicants, however, are not admitting that the information is necessarily relevant or prior art. In addition, Applicants are not representing that the cited information represents the results from a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance the cited information, even if not initialed.

Per the Patent Office's rules, Applicants have not enclosed any of the cited published U.S. patent or patent application references. Applicants, however, are happy to provide copies of any such references upon request from the Examiner.


This statement is being submitted (1) more than 3 months after the filing date of this application, (2) after the issuance of a substantive office action, and (3) before the issuance of a final official action or notice of allowance. The Commissioner is hereby authorized to charge the fee under 37 C.F.R. §1.17(p) to Deposit Account No. **02-2334**. Applicants do not believe that they owe any additional fee in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **02-2334**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to

Express Mail: EV 630723220 US  
Appl. No. 10/723,123  
Information Disclosure Statement  
Attorney Docket No. I-1998.407 US D2

charge such deficiency or overpayment to Deposit Account No. **02-2334**.

Applicants submit that this patent application is in condition for allowance, and request that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'A. Schwartz', is written over a horizontal line.

Aaron L. Schwartz  
Reg. No. 48,181  
Attorney for Applicants

Patent Counsel  
Patent Department  
Intervet Inc.  
P.O. Box 318  
Millsboro, DE 19966  
(302) 933-4034 (tel)  
(302) 934-4305 (fax)

ALS:dap



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/723,123
		Filing Date	November 26, 2006
		First Named Inventor	Theodorus C. Schaap, et al.
		Art Unit	1645
Examiner Name	Baskar, P.		
Attorney Docket Number	I-1998:407 US D2		
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GURNETT, A. et al. "A family of glycolipid linked in Eimeria tenella" Molecular and Biochemical Parasitology, 1990, 41:177-186	
		HOUGHTEN, R.A. et al. "Relative Importance of Position and Individual..." pp21-25 in Vaccines86, Fred Brown, ed., Cold Spring Harbor Laboratory, 1986	
		BURGESS, W. et al. "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast)..." J. of Cell Biology, 1990, 111:2129-2138	
		LAZAR, E. et al. "Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results..." Molecular and Cellular Biology 8:1247-1252 (March 1988)	
		Prosecution History for U.S. Patent Application No. 09/056,806, filed April 8, 1998, Vermeulen, et al.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Express Mail EV 630723220




### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as **Express Mail EV 630723220** US mail in an Express Mail box addressed to:

**Mail Stop: Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on May 4, 2006 .  
Date

  
Signature

Diane Payne  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

**Applicant: Schaap, et al.**  
**Serial No: 10/723,123**  
**Invention Title: Coccidiosis Vaccines**  
**Filing Date: November 26, 2003**  
**Customer No.: 31846**  
**Attorney Docket: I-1998.407 US D2**

Receipt acknowledged of the following documents in the above-identified application:

Information Disclosure Statement (3 pages)  
PTO Form SB-08A (1 page)  
PTO Form SB-08B (1 page)  
Cited References (11 ref.).  
Self-addressed stamped post card (1)